NMRA Neumora Therapeutics Inc.

$NMRA Opened a position at $0.49 Quick backstory for anyone not following this one. In Jun their lead depression drug, navacaprant, missed in its last two Phase 3 trials, making it 0-for-3, and was scrapped. The co cut about 35% of its staff, and the stock has been sold ever since... alongside the rest of small-cap biotech. It just printed a new low, and the MC sits below the $116.8M in cash it reported at Jun 30. What's left is three clinical-stage programs that the market is assigning very little value to. Setup I'm looking at: • Roughly $96M MC against $116.8M cash. Even after adding back ~$54M in term debt, EV is only about $33M. • Interest-only on the debt runs through Apr 2029, so no principal comes due before the readouts. • NMRA-511 Phase 2 moved up from Q1 2027 to year-end 2026. Catalysts into year-end: • NMRA-898 (M4 PAM, schizophrenia): Phase 1 MAD data in 2H 2026, covering safety, PK and CNS exposure. • NMRA-511 (V1aR antagonist, AD agitation): higher-dose MAD cohort in healthy elderly in Q4, with Phase 2 start by year-end. • NMRA-215 (brain-penetrant NLRP3, obesity): IND in Q4, Phase 1 by year-end. To be clear... none of these are sure things. Early-stage programs disappoint all the time, and after Jun the market isn't giving this these guys the benefit of the doubt on any of them. That's the nature of biotech and exactly why the opportunity exists. At an EV around $33M, a lot of disappointment, IMO, is already in the price. Just a healthy starter for now. Early-stage data rarely settles a debate on the first read, and sub-$1 puts a Nas notice on the calendar. I'd rather have room to add into the readouts than be heavy going in. All told, this has been sold far past what the bal sheet implies. I think it starts working in anticipation of the readouts, and if they deliver, this re-rates. It lost the $1 handle in a matter of weeks on tape alone. Clean data takes it back through there quickly, and $1 is where a re-rate starts, not where it ends. The full PL and cap structure breakdown comes once the forensic (and TA) DD wraps. Still working on it. Anyway... just sharing my work. Check everything yourself. As always, DYOR. NFA.

$NMRA If there is even a smallest good news that they have on one of the molecules I'm amazed how the entire float wasn't outright bought at these levels. Even a modest good update should rocket this up to $1.5+

$NMRA Stepped in and scooped 20k shares at $0.37 w/the stock down another 15% today. Again... indiscriminate biotech selling handing out gifts. A simple mean-reversion bounce to late Sept is an immediate 2x, while reclaiming the $1.50 base where it traded all summer before the relentless waterfall breakdown is a 4-bagger from this entry. Downside is heavily buffered by cash... risk/reward here is completely skewed in our favor. Sizing locked in. Letting it play out from here.

$NMRA Found Pinto's employment contract from February 2025. A few things worth noting: The succession plan after Berns — was written into his contract in February 2025. Before navacaprant failed. This wasn’t a reactive appointment after the crash. It was planned. His 3M option grant from the same date is deeply underwater. His largest compensation component has zero value today. His financial interest in recovery is the same as any shareholder’s. Change of control clause pays 2x salary + 2x bonus + full equity acceleration on acquisition. No personal financial incentive to resist a deal. Permitted outside activity listed in the contract: board member at Metsera — the obesity company Pfizer acquired for $10B in November 2025, while he held that seat. The CEO who was chosen before navacaprant failed, held a board seat at a Phase 1 obesity company that sold for $10B is now running NMRA-215. Need to see if they can get 215 results end 2027 without large dilution In short term 898 and 511 matters

$NMRA The entire small biotech sector has been experiencing a decline since the beginning of September... the company hasn't given any specific reasons. Let's hope the year-end announcements help it recover its value.

$NMRA can we get an update on IND for NMRA obesity candidates or something? Let’s get the ball rolling here jeezus we’re being taken down low volume here everyday with no bottom

$NMRA .45 with volume on close makes this interesting for AH and tomorrow gotta break it though!

$NMRA thanks for your insight I didn’t know that AbbVie paid $8.7 billion for M4 PAM. All I knew was that Neumoras M4 PAM had shown same target engagement as COBENFY in a phase 1 study

Added another ~30k shares of $NMRA right here. 🤝 People completely wrote off the pipeline after the Navacaprant Phase 3 flop, but in my view the market has heavily discounted on what’s coming up in H2 2026: -NMRA-215 (Brain-Penetrant NLRP3 Inhibitor for Obesity): IND filing Q4 2026 with Phase 1 launch by year-end. Preclinical data showed up to 19% monotherapy weight loss and 26% paired with semaglutide. Huge potential catalyst if this translates to humans. -NMRA-898 (M4 PAM for Schizophrenia): Phase 1 MAD data drops H2 2026. -NMRA-511 (V1aR Antagonist for AD Agitation): MAD expansion data reporting in Q4 2026 ahead of Phase 2 initiation. At these levels, the risk/reward on the remaining neurology & metabolic pipeline is asymmetrical.

$NMRA Amgen and Arch Capital own 68 million shares, co founder Paul Berns owns 7.6 million also has ties with Arch Capital. That sone strong foundation.

$NMRA People are so stupid, haha—the stock drops 60%, and then they get excited because it goes up 10%! Haha.

$NMRA should get three catalysts by year end, two in November NMRA- 898 , NMRA-511 and last one NMRA-215 by January 1st , with Santa clause rally around the corner it should all come together, although after the price spike some time in January they'll be an offering unless some sort of partnership but im leaning more towards offering .

$NMRA bouncing nicely off the lows, but it’s still ridiculously oversold. A simple reversion to the 50-day SMA puts it at $1.04. That’s not a moonshot call, it’s just a return to the mean.

$NMRA 14% today on barely average volume. No news. No clinical failure. Worth understanding why this keeps drifting lower with no news. It’s not the pipeline. Breaking below $1.00 for 30 consecutive days Nasdaq issue a compliance notice. That automatically triggers forced selling from funds that have mandates prohibiting sub-$1 holdings. They don’t analyse the pipeline — they just sell. Momentum algorithms then read the price action as a signal and pile on. More selling. No buyers stepping up because the same algorithms flag it as a falling knife. The result is what you’re seeing — 14% down days on barely average volume. Not institutions abandoning the thesis. Just structural mechanics with no buying pressure to absorb them. It stops when a catalyst arrives. Not before. Estimated Nov 5 earnings. Q4 catalysts still due. The price and the fundamentals are not telling the same story right now. Clear asymmetrical R/R with market disconnect.

$NMRA This is becoming an absolute joke. Complete silence from management team is either an attempt to shake out the retail or things are heading towards bankruptcy.

$NMRA For what it’s worth. I sold all 250,000 of my shares a little over two weeks ago for roughly $350,000 loss. I’m gambling obviously but if the price action stays the same I’ll buy back in after the wash sale window providing the price stays below my sale price. I think the market is pricing NMRA due to the previous failures and once updates come out for 898, 511 and 215 this one will rise up again. To what levels nobody knows. NMRA has been notorious for not pumping its stock. The lack of PR to keep price up is normal with NMRA. There’s never been hype here, just the results. I don’t think we will need to do a reverse split but NMRA may start the process just to be compliant. Time will tell.

$NMRA I don’t know but this is crazy . I would say I’m going to keep averaging down buying shares. So many catalysts coming. Don’t get it. 1) NMRA-511 has MAD data phase 1b 2nd half 2026. Already shown to be best in class AD agitation drug compared to Auvelity and other approved drugs 2) NMRA-898 has MAD data phase 1b 2nd half 2026 . It’s muscarinic 4 PAM showing same target engagement in phase 1a to Cobenfy in schizophrenia 3) NMRA-215 is an NRLP3 inhibitor showing better than all other drugs of same class in obesity. 19% mono weight loss in preclinical and 26% with semaglutide - IND filing Q4 2026 and phase 1 initiation end of 2026 This doesn’t include any partnerships that could happen. Especially since NLRP3 is the next wanted obesity asset in biotech. I would just keep accumulating this is nuts

$NMRA If you’re thinking of buying in, I would wait for the sell off first. Day traders have 20 percent plus already. My guess is that this will flatten out soon and then sell off. Hard to predict but that’s what Im watching for.

$NMRA Unfortunately, this is destined for reverse split IMO. My guess is they will continue to hit the ATM, even at these absurdly low prices. Too many failures on their report card, and always blaming someone else. This was to be propped up for a buyout, but now they need some extra lipstick on this pig. Sad, greedy management -- and if they R/S, look for Berns and gang to reprice their options, yet again. "RETAIN TALENT".